More on Regeneron Pharma (REGN +1.6%) Q4: swings to net profit of $470M from a net loss of...

|About: Regeneron Pharmaceuticals... (REGN)|By:, SA News Editor

More on Regeneron Pharma (REGN +1.6%) Q4: swings to net profit of $470M from a net loss of $53.4M as sales more than triple, with its Eylea eyecare product bringing in $276M. Earnings also include $127M in collaboration revenues and a non-cash tax benefit of $336M. Forecasts 2013 Eyelea sales of $1.2-1.3B in the U.S. Partner Bayer has started to launch the product overseas. (PR)